$SCWO
374Water Inc

2022 Q1 Form 10-Q Financial Statement

#000165495422006142 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $273.2K $14.50K $0.00
YoY Change -75.83% -100.0%
Cost Of Revenue $248.0K $0.00
YoY Change
Gross Profit $25.25K $0.00
YoY Change
Gross Profit Margin 9.24%
Selling, General & Admin $713.3K $581.7K $40.00K
YoY Change 1683.25% -463.56% -33.33%
% of Gross Profit 2825.51%
Research & Development $185.7K $105.2K $29.19K
YoY Change 536.12% -2.72%
% of Gross Profit 735.41%
Depreciation & Amortization $235.00 $29.74K
YoY Change
% of Gross Profit 0.93%
Operating Expenses $899.0K $686.9K $66.55K
YoY Change 1250.77% -481.63% -33.45%
Operating Profit -$873.7K -$66.55K
YoY Change 1212.84%
Interest Expense $840.00 $320.00 $0.00
YoY Change -99.36% -100.0%
% of Operating Profit
Other Income/Expense, Net $847.00 $330.00 $0.00
YoY Change -99.34%
Pretax Income -$872.9K -$671.8K -$66.55K
YoY Change 1211.56% -303.57% -26.05%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$872.9K -$671.8K -$66.55K
YoY Change 1211.56% -303.57% 9286.6%
Net Earnings / Revenue -319.46% -4633.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$6.900K -$7.146K $0.00
COMMON SHARES
Basic Shares Outstanding 122.8M shares 126.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.24M $11.13M $30.00K
YoY Change 37379.33% 15801.69% -50.0%
Cash & Equivalents $11.24M $11.13M $72.60K
Short-Term Investments
Other Short-Term Assets $167.9K $218.5K $20.00K
YoY Change 739.35% 0.0%
Inventory $0.00
Prepaid Expenses $167.9K $218.5K
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $11.41M $11.35M $50.00K
YoY Change 22723.32% 10905.29% -44.44%
LONG-TERM ASSETS
Property, Plant & Equipment $4.015K $959.00
YoY Change 137.97%
Goodwill
YoY Change
Intangibles $1.047M $1.063M
YoY Change
Long-Term Investments
YoY Change
Other Assets $34.31K $34.74K
YoY Change
Total Long-Term Assets $1.051M $1.064M $0.00
YoY Change 156804.87%
TOTAL ASSETS
Total Short-Term Assets $11.41M $11.35M $50.00K
Total Long-Term Assets $1.051M $1.064M $0.00
Total Assets $12.46M $12.41M $50.00K
YoY Change 24824.62% 11858.21% -44.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $144.0K $62.98K $200.0K
YoY Change -27.98% -21.28% 25.0%
Accrued Expenses
YoY Change
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $290.0K
YoY Change
Total Short-Term Liabilities $910.5K $86.37K $490.0K
YoY Change 85.82% -6.68% 206.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $180.0K
YoY Change -100.0% -55.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $180.0K
YoY Change -100.0% -55.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $910.5K $86.37K $490.0K
Total Long-Term Liabilities $0.00 $0.00 $180.0K
Total Liabilities $910.5K $86.37K $680.0K
YoY Change 33.9% -6.68% 21.43%
SHAREHOLDERS EQUITY
Retained Earnings -$4.033M -$3.160M
YoY Change -68900.67%
Common Stock $12.67K $12.53K
YoY Change 100.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.55M $12.33M -$44.87K
YoY Change
Total Liabilities & Shareholders Equity $12.46M $12.41M $50.00K
YoY Change 24824.62% 11858.21% -44.44%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$872.9K -$671.8K -$66.55K
YoY Change 1211.56% -303.57% 9286.6%
Depreciation, Depletion And Amortization $235.00 $29.74K
YoY Change
Cash From Operating Activities $115.9K -$787.4K -$4.022K
YoY Change -2981.92% -391.61% -93.3%
INVESTING ACTIVITIES
Capital Expenditures $3.291K $1.130K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $19.83K
YoY Change
Cash From Investing Activities -$3.291K $20.96K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 5.050M $4.821K
YoY Change -100.0% -1630.3% -94.64%
NET CHANGE
Cash From Operating Activities $115.9K -787.4K -$4.022K
Cash From Investing Activities -$3.291K 20.96K $0.00
Cash From Financing Activities $0.00 5.050M $4.821K
Net Change In Cash $112.6K 4.284M $799.00
YoY Change 13995.12% -7239.33% -97.34%
FREE CASH FLOW
Cash From Operating Activities $115.9K -$787.4K -$4.022K
Capital Expenditures $3.291K $1.130K $0.00
Free Cash Flow $112.6K -$788.5K -$4.022K
YoY Change -2900.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126680895 shares
CY2022Q1 us-gaap Cash
Cash
11243795 USD
CY2021Q4 us-gaap Cash
Cash
11131175 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
218466 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11349641 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
959 USD
CY2021Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1028114 USD
CY2021Q4 us-gaap Other Assets
OtherAssets
34742 USD
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
167867 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
11411662 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4015 USD
CY2022Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1012327 USD
CY2022Q1 us-gaap Other Assets
OtherAssets
34306 USD
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
1050648 USD
CY2022Q1 us-gaap Assets
Assets
12462310 USD
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
144040 USD
CY2022Q1 us-gaap Other Liabilities
OtherLiabilities
3152 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
910525 USD
CY2022Q1 us-gaap Liabilities
Liabilities
910525 USD
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
27272 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126680895 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125317746 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11551785 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12462310 USD
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1063815 USD
CY2021Q4 us-gaap Assets
Assets
12413456 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
62981 USD
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
763333 USD
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
0 USD
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
23390 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86371 USD
CY2021Q4 us-gaap Liabilities
Liabilities
86371 USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
3 USD
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12531 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
15474566 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3160015 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
12327085 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12413456 USD
CY2022Q1 us-gaap Revenues
Revenues
273231 USD
CY2021Q1 us-gaap Revenues
Revenues
0 USD
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
247986 USD
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
25245 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
0 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185653 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29185 USD
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
301235 USD
CY2021Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
18686 USD
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
150658 USD
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
8203 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
261403 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10477 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
898950 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
66551 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-873705 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-66551 USD
CY2022Q1 us-gaap Interest Income Operating
InterestIncomeOperating
840 USD
CY2021Q1 us-gaap Interest Income Operating
InterestIncomeOperating
0 USD
CY2022Q1 us-gaap Other Income
OtherIncome
7 USD
CY2021Q1 us-gaap Other Income
OtherIncome
0 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
847 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-872858 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66551 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-872858 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-66551 USD
CY2022Q1 scwo Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.01
CY2021Q1 scwo Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.00
CY2022Q1 scwo Weighted Average Common Shares Outstanding Basic And Diluted
WeightedAverageCommonSharesOutstandingBasicAndDiluted
126499142 shares
CY2021Q1 scwo Weighted Average Common Shares Outstanding Basic And Diluted
WeightedAverageCommonSharesOutstandingBasicAndDiluted
62410452 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
12327085 USD
CY2022Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
97558 USD
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-20238 USD
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1200 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115911 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4022 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3291 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3291 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021Q2 scwo Shares Issued To Former Holder
SharesIssuedToFormerHolder
62410452 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-872858 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11551785 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11250 USD
CY2021Q1 us-gaap Accretion Expense
AccretionExpense
10433 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-66551 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-44868 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-872858 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-66551 USD
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
16458 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10433 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
24340 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
81059 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
28966 USD
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
763333 USD
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-50599 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4821 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4821 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
112620 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
799 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11131175 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71799 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11243795 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72598 USD
CY2022Q1 scwo Conversion Of Stock Amount Issued
ConversionOfStockAmountIssued
133 USD
CY2021Q1 scwo Conversion Of Stock Amount Issued
ConversionOfStockAmountIssued
0 USD
CY2021Q2 scwo Merger Effect Description
MergerEffectDescription
Immediately following the Merger, Private 374Water changed its name to 374Water Systems Inc and PowerVerde changed its name to 374Water, Inc. After the Merger, the former Private 374Water stockholders own 64.2% of the Company’s issued and outstanding common stock and 53.8% of the Company’s issued and outstanding voting stock which includes the Preferred Stock.
CY2022Q1 us-gaap Depreciation
Depreciation
235 USD
CY2022Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
27272 shares
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1046633 USD
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 scwo Warrants Outstanding Series One Shares
WarrantsOutstandingSeriesOneShares
1250000 shares
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.50
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
437500 USD
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
2.85
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185653 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29185 USD
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12660000 shares
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the fair value of equity-based compensation, useful lives of intangible assets, and valuation allowance against deferred tax assets.</p>
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
440125 shares
CY2022Q1 us-gaap Capital
Capital
10501137 USD
CY2021Q4 us-gaap Capital
Capital
11263270 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4032873 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-872858 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
115911 USD
CY2021Q4 scwo Proceeds From Stock Issued Upon Warrants Exercised Amount
ProceedsFromStockIssuedUponWarrantsExercisedAmount
1134499 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1062856 USD
CY2022Q1 scwo Intangible Assets Additions
IntangibleAssetsAdditions
0 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16223 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1046633 USD
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
16458 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
CY2022Q1 scwo Weighted Average Exercise Price Exercised
WeightedAverageExercisePriceExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.50
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
437500 USD
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y8M19D
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 scwo Liability For Preferred Stock Shares
LiabilityForPreferredStockShares
50000 USD
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126680895 shares
CY2022Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1363149 shares
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
48663 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
64884 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
64884 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
64884 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
64884 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
738434 USD
CY2021Q2 scwo Number Of Warrant Purchase
NumberOfWarrantPurchase
3783333 shares
CY2021Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.30
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.37
CY2021Q2 scwo Aggregate Fair Value Of Warrant
AggregateFairValueOfWarrant
1399833 USD
CY2021Q4 scwo Stock Issued Upon Warrant Exercised
StockIssuedUponWarrantExercised
3783333 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.50
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
437500 USD
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y11M15D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q1 scwo Stock In Excess Percentage Of Outstanding Share
StockInExcessPercentageOfOutstandingShare
0.05 pure
CY2022Q1 us-gaap Related Party Costs
RelatedPartyCosts
50000 USD
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
763333 USD
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2022Q1 scwo Deferred Revenue Percentage
DeferredRevenuePercentage
1 pure

Files In Submission

Name View Source Status
0001654954-22-006142-index-headers.html Edgar Link pending
0001654954-22-006142-index.html Edgar Link pending
0001654954-22-006142.txt Edgar Link pending
0001654954-22-006142-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scwo-20220331.xsd Edgar Link pending
scwo-20220331_cal.xml Edgar Link unprocessable
scwo-20220331_def.xml Edgar Link unprocessable
scwo-20220331_lab.xml Edgar Link unprocessable
scwo-20220331_pre.xml Edgar Link unprocessable
scwo_10q.htm Edgar Link pending
scwo_10q_htm.xml Edgar Link completed
scwo_ex311.htm Edgar Link pending
scwo_ex312.htm Edgar Link pending
scwo_ex321.htm Edgar Link pending
scwo_ex322.htm Edgar Link pending
Show.js Edgar Link pending